Edward Ruby
Endocrinology · Darby, PANPI 1598788549
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 106 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $466 and has fallen 75.4% since, to $115 in 2025. Among endocrinology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 106 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$297
- Novo Nordisk$251
- AbbVie$204
- Amneal Pharmaceuticals LLC$171
- Radius Health, Inc.$150
- Abbott$149
- plus $950 from 19 others
What the payments were for
- Food & beverage$2,11597%
- Gifts$593%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 10 | $297 |
| Novo Nordisk | 13 | $251 |
| AbbVie | 11 | $204 |
| Amneal Pharmaceuticals LLC | 11 | $171 |
| Radius Health, Inc. | 9 | $150 |
| Abbott | 2 | $149 |
| Lilly USA, LLC | 9 | $149 |
| Amgen(2 entities) | 6 | $102 |
| Xeris Pharmaceuticals, Inc. | 5 | $100 |
| Novartis | 5 | $84 |
| BD | 2 | $69 |
| Mannkind Corporation | 1 | $59 |
| Johnson & Johnson | 2 | $49 |
| Ipsen Biopharmaceuticals, Inc | 3 | $47 |
| Boehringer Ingelheim | 2 | $45 |
| AstraZeneca | 2 | $37 |
| Corcept Therapeutics | 2 | $34 |
| Shire North American Group Inc | 2 | $33 |
| Dexcom, Inc. | 2 | $32 |
| IBSA Pharma Inc. | 2 | $30 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Pfizer | 1 | $18 |
| Intuity Medical Inc | 1 | $18 |
| Chiasma, Inc. | 1 | $13 |
| Bayer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FreeStyle Libre$135
- TOUJEO$114
How this compares
$2,174 in reported general payments places this provider in the 90th percentile of 22 endocrinology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 147 | $178,334 |
| JanuviaSitagliptin Phosphate | 113 | $131,088 |
| JardianceEmpagliflozin | 62 | $80,236 |
| MounjaroTirzepatide | 37 | $69,665 |
| SynthroidLevothyroxine Sodium | 598 | $66,091 |
| Norditropin FlexproSomatropin | 16 | $48,067 |
| TradjentaLinagliptin | 35 | $35,623 |
| ProliaDenosumab | 19 | $32,796 |
| TrulicityDulaglutide | 15 | $23,835 |
| FarxigaDapagliflozin Propanediol | 20 | $22,234 |
| Victoza 3-PakLiraglutide | 11 | $14,784 |
| Humalog Kwikpen U-100Insulin Lispro | 41 | $12,147 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 31 | $11,488 |
| Novolog FlexpenInsulin Aspart | 47 | $9,221 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $7,808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $251 | $184,433167 claims |
| Boehringer IngelheimJardiance, Tradjenta | $45 | $115,85897 claims |
| Lilly USA, LLCMounjaro, Trulicity | $149 | $93,50052 claims |
| AbbVieSynthroid | $204 | $66,091598 claims |
| AmgenProlia | $102 | $32,79619 claims |
| AstraZenecaFarxiga | $37 | $22,23420 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $171 | $4,357260 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 22 endocrinology providers in Pennsylvania.
Other endocrinology in Darby
- Sam JosephFeasterville Trevose$3K
- Mohammad ArastuBethlehem$2K
- Diana PinkhasovaPittsburgh$2K
- Javier Ocampo MascaroPhiladelphia$671
- Maja Stefanovic-RacicPittsburgh$491
- Steven HodakPittsburgh$190
- Susan GreenspanPittsburgh$162
- Julia KharlipPhiladelphia$0
- Daniel RubinPhiladelphia$0
- Hamdee AttallahPhiladelphia$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.